What if the future of multiple sclerosis treatment could go beyond suppressing inflammation - and actually help protect the brain?In this episode of Rx for Biotech, host Chris Leidli sits down with Jason Tardio, President & COO of Immunic Therapeutics, to discuss the evolving future of treatment for Multiple Sclerosis (MS), one of the most complex autoimmune and neurodegenerative diseases affecting millions worldwide.Jason shares his deep experience leading major MS franchises at Biogen and Novartis, explains how MS attacks the brain and spinal cord, and breaks down why many current therapies focus primarily on inflammation but may not fully address the neurodegeneration driving long-term disability.The conversation also explores Immunic’s lead investigational therapy, vidofludimus calcium, an oral once-daily treatment being studied in Phase 3 clinical trials for relapsing multiple sclerosis. The company believes the therapy may offer a unique dual approach by targeting both neuroinflammation and neurodegeneration.Topics discussed include:• What causes multiple sclerosis• Early symptoms and diagnosis of MS• How MRI imaging transformed MS care• Why MS remains difficult to treat• The difference between inflammation and neurodegeneration• Oral therapies vs infusions and injectables• Progressive multiple sclerosis and unmet patient needs• The future of neuroscience, immunotherapy, and personalized medicineFor patients, caregivers, healthcare providers, and anyone interested in the future of neurology and autoimmune disease treatment, this episode offers an accessible and hopeful look at where MS care may be headed next.